Vivanza Biosciences Ltd
07 Nov 2026 12:00 AM
Vivanza Biosciences Ltd consolidated sales up 22.82% on year in Q2FY2027,
Vivanza Biosciences Ltd share price inched up 3.50% to Rs 1.48 after the company`s net profit slipped by 6.67% to Rs 0.14 crore, while revenue from operations increased sharply by 22.82% to Rs 11.41 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, easing 5.54%. It has marginally improved by 2.89% over last one week and crept higher by 3.43% in last one month while the market capitalization of Vivanza Biosciences Ltd has eased by 3.90% and 21.69% in the same period respectively.
Profit before tax (PBT) of Vivanza Biosciences Ltd stood at Rs 0.17 crore in Q2 FY27, tanking 69.64% year-on-year, and slipping 5.56% quarter-on-quarter. EBITDA came in at Rs 0 crore, plunging by 54.24% YoY and tumbling by 161.36% sequentially.
Total expenses rose by 19.32% to Rs 11.18 crore in Q2FY27 over Q2FY26. During the quarter, employee benefits expense was at Rs 0.1 crore, remaining flat YoY.
For FY26, revenue from operations soared by 1462.13% to Rs 115.91 crore, while net profit witnessed a sharp fall of 158.21% to Rs 0.39 crore, compared to previous FY. EBITDA tanked by 142% to Rs 0.62 crore, and PBT plunged by 180.60% to Rs 0.54 crore compared to previous FY.
The company`s consolidated net cash flow from operating activities stood at Rs 2.58 crore in FY26, as against Rs 2.5 crore in FY25.
Vivanza Biosciences Ltd nosedived by 24.87% in last one year, underperforming the benchmark BSE Sensex which has slipped by 2.74% during the same period.
Vivanza Biosciences Ltd
03 Nov 2026 12:00 AM
Vivanza Biosciences delays board meeting to November 6 to review financial results,
Vivanza Biosciences Limited has postponed its board meeting, originally scheduled for November 3, 2026, to Friday, November 6, 2026, at 3:30 P.M. due to unavoidable circumstances, to discuss the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, and other business matters.
Vivanza Biosciences Ltd
28 Oct 2026 12:00 AM
Vivanza Biosciences to review quarterly and half-year financials at November 3 meeting,
Vivanza Biosciences Limited will hold a meeting of its Board of Directors on November 3, 2026, at 3:30 P.M. to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with a limited review report. The company has closed the trading window for directors, officers, key managerial personnel, and designated persons until 48 hours after the unaudited financial results are declared.
Vivanza Biosciences Ltd
08 Oct 2026 12:00 AM
Vivanza Biosciences confirms no new public funding and regulatory compliance,
Vivanza Biosciences Limited informed the BSE Limited on October 8, 2026, that the company has not raised any further funds through a public issue, rights issue, or preferential issue, and therefore, the statement of deviation or variation under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable.
Vivanza Biosciences Ltd
02 Oct 2026 12:00 AM
Vivanza Biosciences receives confirmation certificate from Purva Sharegistry for Q3 2026,
Vivanza Biosciences Limited informed the BSE Limited that it has received a confirmation certificate from Purva Sharegistry (I) Pvt. Ltd., its Registrar and Share Transfer Agent, for the quarter ended September 30, 2026, under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
Subscribe for our
newsletter
newsletter
HSL Mobile App